{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-062599","form_type":"8-K","ticker":"ALUR","cik":"0001964979","company_name":"ALLURION TECHNOLOGIES, INC.","filed_at":"2026-02-23T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.893694+00:00","generated_at":"2026-05-16T01:16:25.907588+00:00","sec_items":["7.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"FDA grants PMA approval for Allurion gastric balloon system for obesity","bullets":["Allurion Smart Capsule approved for adults 22-65 with BMI 30-40 kg/m² after unsuccessful weight loss attempt.","Balloon swallowed in 15-min office visit, no surgery/endoscopy/anesthesia; stays ~4 months, then passes naturally.","AUDACITY pivotal trial data supported approval; over 200,000 patients treated outside US with 14% total body weight loss.","Opens access to ~80 million US adults with obesity; alternative to GLP-1s and bariatric surgery.","Company cited 65% GLP-1 discontinuation rate within first year and rapid weight regain as unmet need."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-062599","json":"https://secwatch.observer/filing/0001193125-26-062599.json","markdown":"https://secwatch.observer/filing/0001193125-26-062599.md","text":"https://secwatch.observer/filing/0001193125-26-062599.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1964979/000119312526062599/0001193125-26-062599-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1964979/000119312526062599/alur-20260223.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T01:16:25.907588+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"comparable_filings":[{"accession":"0001213900-26-062935","ticker":"ATNM","company_name":"Actinium Pharmaceuticals, Inc.","filed_at":"2026-05-29T21:10:41+00:00","headline":"Actinium receives NYSE American non-compliance notice for low stockholders' equity; must submit plan by June 26","event_type":"regulatory","sec_items":["3.01","7.01","9.01"],"materiality_score":0.75,"calibrated_materiality_score":0.75,"match_reasons":["same SEC item: 7.01, 9.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-062935","json":"https://secwatch.observer/filing/0001213900-26-062935.json","markdown":"https://secwatch.observer/filing/0001213900-26-062935.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1388320/000121390026062935/0001213900-26-062935-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1388320/000121390026062935/ea0292691-8k_actinium.htm"},"side_by_side_evidence":null},{"accession":"0001104659-26-068002","ticker":"REPL","company_name":"Replimune Group, Inc.","filed_at":"2026-05-29T13:56:10+00:00","headline":"Replimune to resubmit RP1 BLA for advanced melanoma; FDA agrees to prioritize review","event_type":"regulatory","sec_items":["7.01","9.01"],"materiality_score":0.8,"calibrated_materiality_score":0.8,"match_reasons":["same SEC item: 7.01, 9.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-068002","json":"https://secwatch.observer/filing/0001104659-26-068002.json","markdown":"https://secwatch.observer/filing/0001104659-26-068002.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1737953/000110465926068002/0001104659-26-068002-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1737953/000110465926068002/tm2615980d1_8k.htm"},"side_by_side_evidence":null},{"accession":"0001493152-26-025277","ticker":"VSTD","company_name":"Vestand Inc.","filed_at":"2026-05-26T21:18:59+00:00","headline":"Vestand receives Nasdaq delisting notice for late quarterly and annual filings","event_type":"regulatory","sec_items":["3.01","7.01","9.01"],"materiality_score":0.85,"calibrated_materiality_score":0.85,"match_reasons":["same SEC item: 7.01, 9.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-025277","json":"https://secwatch.observer/filing/0001493152-26-025277.json","markdown":"https://secwatch.observer/filing/0001493152-26-025277.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1898604/000149315226025277/0001493152-26-025277-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1898604/000149315226025277/form8-k.htm"},"side_by_side_evidence":null},{"accession":"0001213900-26-061008","ticker":"MDAI","company_name":"Spectral AI, Inc.","filed_at":"2026-05-26T20:00:52+00:00","headline":"Spectral AI receives FDA De Novo clearance for DeepView System for burn indication","event_type":"regulatory","sec_items":["7.01","9.01"],"materiality_score":0.85,"calibrated_materiality_score":0.85,"match_reasons":["same SEC item: 7.01, 9.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-061008","json":"https://secwatch.observer/filing/0001213900-26-061008.json","markdown":"https://secwatch.observer/filing/0001213900-26-061008.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1833498/000121390026061008/0001213900-26-061008-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1833498/000121390026061008/ea0292182-8k_spectral.htm"},"side_by_side_evidence":null},{"accession":"0001836875-26-000036","ticker":"NVVE","company_name":"Nuvve Holding Corp.","filed_at":"2026-05-22T22:35:13+00:00","headline":"Nuvve receives Nasdaq delisting notice for late Q1 10-Q filing; already under $1.00 bid price review","event_type":"regulatory","sec_items":["3.01","7.01","9.01"],"materiality_score":0.75,"calibrated_materiality_score":0.75,"match_reasons":["same SEC item: 7.01, 9.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001836875-26-000036","json":"https://secwatch.observer/filing/0001836875-26-000036.json","markdown":"https://secwatch.observer/filing/0001836875-26-000036.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1836875/000183687526000036/0001836875-26-000036-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1836875/000183687526000036/nvve-20260522.htm"},"side_by_side_evidence":null},{"accession":"0001104659-26-064861","ticker":"RGTI","company_name":"Rigetti Computing, Inc.","filed_at":"2026-05-21T11:30:49+00:00","headline":"Rigetti signs LOI for up to $100M CHIPS Act award for quantum R&D; government to receive equity","event_type":"regulatory","sec_items":["3.02","8.01","7.01","9.01"],"materiality_score":0.8,"calibrated_materiality_score":0.8,"match_reasons":["same SEC item: 7.01, 9.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-064861","json":"https://secwatch.observer/filing/0001104659-26-064861.json","markdown":"https://secwatch.observer/filing/0001104659-26-064861.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1838359/000110465926064861/0001104659-26-064861-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1838359/000110465926064861/tm2615300d1_8k.htm"},"side_by_side_evidence":null},{"accession":"0001140361-26-020845","ticker":"GYRE","company_name":"GYRE THERAPEUTICS, INC.","filed_at":"2026-05-12T21:03:02+00:00","headline":"Gyre Therapeutics' NDA for F351 accepted by China's NMPA for CHB-induced liver fibrosis","event_type":"regulatory","sec_items":["7.01","9.01"],"materiality_score":0.8,"calibrated_materiality_score":0.8,"match_reasons":["same SEC item: 7.01, 9.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-26-020845","json":"https://secwatch.observer/filing/0001140361-26-020845.json","markdown":"https://secwatch.observer/filing/0001140361-26-020845.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1124105/000114036126020845/0001140361-26-020845-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1124105/000114036126020845/ef20073066_8k.htm"},"side_by_side_evidence":null},{"accession":"0001821586-26-000005","ticker":"MLTX","company_name":"MoonLake Immunotherapeutics","filed_at":"2026-05-11T23:59:59+00:00","headline":"MoonLake aligns with FDA on BLA for sonelokimab in HS; Q1 cash $357.9M","event_type":"regulatory","sec_items":["2.02","7.01","9.01"],"materiality_score":0.85,"calibrated_materiality_score":0.85,"match_reasons":["same SEC item: 7.01, 9.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001821586-26-000005","json":"https://secwatch.observer/filing/0001821586-26-000005.json","markdown":"https://secwatch.observer/filing/0001821586-26-000005.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1821586/000182158626000005/0001821586-26-000005-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1821586/000182158626000005/mnlk-20260510.htm"},"side_by_side_evidence":null}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}